[ A23-48 ] Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V
Last updated 17.11.2023
Project no.:
A23-48
Commission:
Commission awarded on 31.05.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy
- Patients < 65 years who are eligible for high-dose therapy: hint of a non-quantifiable added benefit
- Patients ≥ 65 years who are eligible for high-dose therapy: added benefit not proven
- Patients with diffuse large B-cell lymphoma or high grade B-cell lymphoma who are not eligible for high-dose therapy: added benefit not proven
- Patients with primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B who are not eligible for high-dose therapy: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-90 | Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-98 | Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48 | Commission completed |
Federal Joint Committee (G-BA)
2023-11-17 A G-BA decision was published.